StockNews.com Begins Coverage on Eagle Pharmaceuticals (NASDAQ:EGRX)

Investment analysts at StockNews.com began coverage on shares of Eagle Pharmaceuticals (NASDAQ:EGRX) in a research note issued to investors on Monday. The brokerage set a “hold” rating on the specialty pharmaceutical company’s stock.

Eagle Pharmaceuticals Price Performance

Shares of EGRX opened at $1.17 on Monday. The business’s 50-day moving average price is $0.72 and its 200 day moving average price is $1.85. Eagle Pharmaceuticals has a 1-year low of $0.00 and a 1-year high of $6.81.

Institutional Investors Weigh In On Eagle Pharmaceuticals

A number of large investors have recently made changes to their positions in the company. Creative Planning purchased a new position in Eagle Pharmaceuticals during the 3rd quarter worth approximately $59,000. Jane Street Group LLC purchased a new position in shares of Eagle Pharmaceuticals during the third quarter valued at $96,000. DGS Capital Management LLC raised its position in Eagle Pharmaceuticals by 44.9% during the third quarter. DGS Capital Management LLC now owns 71,728 shares of the specialty pharmaceutical company’s stock valued at $268,000 after buying an additional 22,239 shares during the period. Jacobs Levy Equity Management Inc. purchased a new stake in Eagle Pharmaceuticals in the 3rd quarter worth about $453,000. Finally, RBF Capital LLC boosted its position in Eagle Pharmaceuticals by 11.7% during the 3rd quarter. RBF Capital LLC now owns 143,078 shares of the specialty pharmaceutical company’s stock worth $534,000 after acquiring an additional 14,991 shares during the period. Institutional investors and hedge funds own 85.36% of the company’s stock.

About Eagle Pharmaceuticals

Eagle Pharmaceuticals, Inc, a pharmaceutical company, focuses on developing and commercializing product candidates to treat diseases of the central nervous system or metabolic critical care, and oncology in the United States. The company offers Ryanodex for malignant hyperthermia; and Belrapzo and Bendeka for chronic lymphocytic leukemia and indolent B-cell non-Hodgkin’s lymphoma.